HI
NBIX icon

HBK Investments’s Neurocrine Biosciences NBIX Stock Holding History

HBK Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,000
Closed -$428K – 1248
2018
Q4 		$428K Sell
6,000
-2,883
-32% -$276K ﹤0.01% 936
2018
Q3 		$1.09M Sell
8,883
-7,599
-46% -$862K 0.01% 692
2018
Q2 		$1.62M Buy
+16,482
New +$1.48M 0.01% 527
2017
Q1 		– Sell
-11,300
Closed -$437K – 769
2016
Q4 		$437K Buy
+11,300
New +$512K ﹤0.01% 573
2016
Q3 		– Sell
-42,267
Closed -$1.92M – 942
2016
Q2 		$1.92M Buy
42,267
+27,679
+190% +$1.27M 0.01% 434
2016
Q1 		$577K Sell
14,588
-25,812
-64% -$1.02M 0.01% 705
2015
Q4 		$2.29M Sell
40,400
-75,734
-65% -$3.85M 0.02% 381
2015
Q3 		$4.62M Buy
+116,134
New +$5.61M 0.05% 240
2014
Q2 		– Sell
-46,500
Closed -$749K – 994
2014
Q1 		$749K Sell
46,500
-25,700
-36% -$440K 0.01% 561
2013
Q4 		$674K Buy
72,200
+15,700
+28% +$153K 0.01% 575
2013
Q3 		$640K Sell
56,500
-2,400
-4% -$33K 0.01% 572
2013
Q2 		$788K Buy
+58,900
New +$724K 0.01% 464

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBK Investments's NBIX Position: Q1 2019 in Review

HBK Investments sold out of Neurocrine Biosciences (NBIX) in Q1 2019, closing a stake of 6,000 shares — an estimated $428K sold.

HBK Investments first reported a position in NBIX in Q2 2013 and held it in 12 quarters. The position peaked at $4.62M in Q3 2015. 325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • HBK Investments reported no remaining Neurocrine Biosciences position as of Q1 2019 after selling out during the quarter.
  • HBK Investments sold 6,000 Neurocrine Biosciences shares in Q1 2019, an estimated $428K.
  • HBK Investments first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 12 quarters.
  • HBK Investments's Neurocrine Biosciences position peaked at $4.62M in Q3 2015.
  • 325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on HBK Investments's 13F filing for Q1 2019, filed 15 May 2019.